Castlefield Investment Partners LLP Purchases New Holdings in Boston Scientific Corporation $BSX

Castlefield Investment Partners LLP acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 56,907 shares of the medical equipment provider’s stock, valued at approximately $2,429,000. Boston Scientific comprises approximately 1.6% of Castlefield Investment Partners LLP’s investment portfolio, making the stock its 26th largest position.

Other hedge funds have also recently bought and sold shares of the company. Kelleher Financial Advisors acquired a new stake in Boston Scientific in the second quarter worth about $25,000. FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $28,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Up 0.0%

NYSE BSX opened at $50.39 on Monday. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $46.34 and a 200-day moving average of $57.62. The company has a market cap of $73.03 billion, a PE ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the company earned $0.75 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Jefferies Financial Group cut their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a report on Wednesday, July 29th. Oppenheimer decreased their price objective on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 27th. Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Finally, Truist Financial decreased their price target on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Insider Transactions at Boston Scientific

In other news, Director David C. Habiger acquired 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 194,522 shares of company stock worth $9,385,210 in the last ninety days. Insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.